Plus Therapeutics Stock Alpha and Beta Analysis
| PSTV Stock | USD 1.23 0.05 4.24% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Plus Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Plus Therapeutics over a specified time horizon. Remember, high Plus Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Plus Therapeutics' market risk premium analysis include:
Beta 0.0583 | Alpha (0.10) | Risk 5.76 | Sharpe Ratio (0.01) | Expected Return (0.07) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Plus |
Plus Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Plus Therapeutics market risk premium is the additional return an investor will receive from holding Plus Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Plus Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Plus Therapeutics' performance over market.| α | -0.1 | β | 0.06 |
Plus Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Plus Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Plus Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Plus Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Plus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Plus Therapeutics shares will generate the highest return on investment. By understating and applying Plus Therapeutics stock market price indicators, traders can identify Plus Therapeutics position entry and exit signals to maximize returns.
Plus Therapeutics Return and Market Media
The median price of Plus Therapeutics for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 1.38 with a coefficient of variation of 9.16. The daily time series for the period is distributed with a sample standard deviation of 0.13, arithmetic mean of 1.39, and mean deviation of 0.1. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Andrew Sims of 4098 shares of Plus Therapeutics at 1.27 subject to Rule 16b-3 | 09/10/2024 |
2 | Acquisition by Hedrick Marc H of 197595 shares of Plus Therapeutics at 1.26 subject to Rule 16b-3 | 09/11/2024 |
3 | Acquisition by Hawkins Richard J of 6285 shares of Plus Therapeutics at 1.3543 subject to Rule 16b-3 | 09/12/2024 |
4 | Acquisition by Hawkins Richard J of 4000 shares of Plus Therapeutics at 1.499 subject to Rule 16b-3 | 09/13/2024 |
5 | Plus Therapeutics director acquires 8.5k in stock - Investing.com | 09/16/2024 |
6 | Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting | 10/01/2024 |
7 | Acquisition by Clowes Howard of 3000 shares of Plus Therapeutics at 2.42 subject to Rule 16b-3 | 10/10/2024 |
8 | Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 | 11/05/2024 |
9 | Organogenesis Tops Q3 Earnings and Revenue Estimates | 11/12/2024 |
10 | Plus Therapeutics GAAP EPS of -0.37 beats by 0.19, revenue of 1.45M beats by 0.31M | 11/14/2024 |
11 | What is HC Wainwrights Estimate for PSTV FY2028 Earnings | 11/20/2024 |
12 | Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases | 11/21/2024 |
13 | Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal ... | 11/25/2024 |
About Plus Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Plus or other stocks. Alpha measures the amount that position in Plus Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Dividend Yield | 0.002524 | 0.002244 | Price To Sales Ratio | 1.12 | 1.06 |
Plus Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Plus Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Plus Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Plus Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Plus Therapeutics. Please utilize our Beneish M Score to check the likelihood of Plus Therapeutics' management manipulating its earnings.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 18th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Plus Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Plus Stock Analysis
When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.